Mounjaro's Sales Soar 502% as India's GLP-1 Market Booms

Mounjaro, the superstar of diabetes drugs, just pulled off a jaw-dropping 502% sales surge in India, raking in ₹1,256 crore in a year! The GLP-1 market is flexing its muscles, with injectables strutting around with an 86% market share. Sure, unit sales dipped—probably because patients are leveling up to higher doses—but who cares when you’re the top dog in the game? Inject some fun into healthcare!